four new cultivation partners within a month – Biotech Investments

Cantourage sets corporate record: four new cultivation partners within a month

BERLIN, June 29, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of medical cannabis, has announced that it has been able to partner with four major producers to supply the European medical cannabis market in only one month, namely: Green Karat, Costa Canna, MedColCanna and Roxton Air. This unprecedented pace of expanding the partner network attests to Cantourage’s stronger position and continued momentum in the European cannabis market. This means an even better supply of high-quality cannabis flower in the future for people in Germany, who can already obtain medical cannabis as a medicine through pharmacies.

Cantourage has laid the groundwork for these partnerships in recent years, establishing a proven and efficient model with its “Fast Track Access” platform that enables the best international growers to bring their products to the European market quickly and efficiently. Since the platform’s launch in 2021, Cantourage has brought a total of 17 growers to Germany. In the first half of 2023, eight partners launched a product on the German market for the first time, including four now in June alone.
The newly acquired partners bring a variety of expertise and specialties to the partnership:

Green Karat: With four specially equipped flower rooms and an annual cultivation capacity of 1,500 kg, Green Karat is ideally positioned for the cultivation of craft cannabis. Headquartered in Québec, Canada, the company is run by a small but highly skilled team with many years of experience, largely made up of friends and family of the founders, who have been working together in a spirit of trust for a long time. Green Karat places great importance on growing small batches of premium cannabis flowers to ensure outstanding quality, which also enjoys great popularity in the cannabis pioneer country Canada.

Costa Canna operates its state-of-the-art cannabis cultivation facility on Vancouver Island, British Columbia, Canada. The company is known for its stringent breeding practices and advanced genetics, with the goal of developing some of the most exceptional cannabis cultivars in the industry. In partnership with the Cowichan Tribes (First Nations), the company offers an extensive portfolio of products that it distributes to the Canadian market through medical platform partners as well as retail stores.

MedColCanna, a company based in Colombia that specializes in the cultivation of high quality THC flower. As one of South America’s leading cannabis growers, MedColCanna is known for environmental sustainability and social responsibility. For example, the company utilizes the country’s abundant renewable energy sources in the Andes and recycles rainwater to irrigate its cultivation facility. MedColCanna is also committed to fair working conditions and wages in its home country, as well as a non-judgmental approach to medical cannabis.

Roxton Air, a young cannabis cultivation company based in the small town of Roxton Pond near Montréal, Canada, stands out for its innovative aeroponic vertical cannabis cultivation. The vertical cultivation towers allow for optimal use of space while ensuring meticulous monitoring and control of each plant to ensure consistent high quality.
“The fact that we were able to bring four new, high-profile cannabis cultivators to the German market in only one month underscores the attractiveness and effectiveness of our platform. More and more top-notch international growers are now approaching us to partner up. New partnerships are thus becoming easier and faster for us to establish. This shows that our model not only works, but is also perceived as a showcase model in the industry. We are proud to be in a position to offer patients an even greater choice of premium quality medical cannabis products.” Philip Schetter, CEO of Cantourage, is convinced.
 
About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com 

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.